$4.14
+0.21 (+5.34%)
Open$4.16
Previous Close$3.93
Day High$4.20
Day Low$4.00
52W High$29.52
52W Low$22.62
Volume—
Avg Volume383.0K
Market Cap163.65M
P/E Ratio25.47
EPS$0.98
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+619.3% upside
Current
$4.14
$4.14
Target
$29.78
$29.78
$19.47
$29.78 avg
$34.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 184.51M | 172.01M | 149.83M |
| Net Income | 6.70M | 5.27M | 5.04M |
| Profit Margin | 3.6% | 3.1% | 3.4% |
| EBITDA | 12.90M | 10.88M | 9.08M |
| Free Cash Flow | 3.45M | 3.47M | 2.49M |
| Rev Growth | +0.4% | +18.6% | +9.2% |
| Debt/Equity | 0.16 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |